TGFB1 and neoplasm: BRAFV600E‐mutant CMS4 tumors of the TCGA dataset display higher levels of TGFβ pathway activation based on gene expression compared with CMS1 BRAFV600E‐mutant CRCs, suggesting that the distinction installed early in tumor development is maintained at the carcinoma stage.